Patents by Inventor B. Michael Silber

B. Michael Silber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220133918
    Abstract: Compounds derived from celecoxib and valdecoxib, and methods of use thereof, are disclosed. The compounds are useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The compounds contain a radioactive agent which permits imaging. The compounds concentrate at sites of increased cyclooxygenase expression, such as areas of increased COX-2 expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections, assessing efficacy of diagnosis and treatment of rheumatoid arthritis, and assessing the need for treatment with opioid drugs.
    Type: Application
    Filed: October 7, 2021
    Publication date: May 5, 2022
    Inventors: B. Michael SILBER, Frank Kayser, Mark A. Reiley
  • Publication number: 20220017432
    Abstract: Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
    Type: Application
    Filed: January 26, 2021
    Publication date: January 20, 2022
    Inventors: Mark A. REILEY, B. Michael SILBER, Julio MEDINA, Frank KAYSER, William D. SHRADER
  • Publication number: 20190169084
    Abstract: Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
    Type: Application
    Filed: July 2, 2018
    Publication date: June 6, 2019
    Inventors: Mark A. REILEY, B. Michael SILBER, Julio MEDINA, Frank KAYSER, William D. SHRADER
  • Patent number: 10053478
    Abstract: The present disclosure provides platinum-containing conjugates that selectively target and kill tumor/cancer cells. The conjugates contain a moiety that selectively targets COX-2, which is overexpressed by a broad range of tumor/cancer cells.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 21, 2018
    Assignee: REILEY PHARMACEUTICALS, INC.
    Inventors: Mark A. Reiley, B. Michael Silber, Xiaoqi Chen
  • Publication number: 20180162784
    Abstract: Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
    Type: Application
    Filed: November 9, 2017
    Publication date: June 14, 2018
    Inventors: Mark A. REILEY, B. Michael SILBER, Julio MEDINA, Frank KAYSER, William D. SHRADER
  • Patent number: 9850183
    Abstract: Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: December 26, 2017
    Assignee: Reiley Pharmaceuticals, Inc.
    Inventors: Mark A. Reiley, B. Michael Silber, Julio Medina, Frank Kayser, William D. Shrader
  • Publication number: 20160200752
    Abstract: The present disclosure provides platinum-containing conjugates that selectively target and kill tumor/cancer cells. The conjugates contain a moiety that selectively targets COX-2, which is overexpressed by a broad range of tumor/cancer cells.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 14, 2016
    Inventors: Mark A. REILEY, B. Michael SILBER, Xiaoqi CHEN
  • Publication number: 20150374858
    Abstract: Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
    Type: Application
    Filed: June 22, 2015
    Publication date: December 31, 2015
    Inventors: Mark A. REILEY, B. Michael SILBER, Julio MEDINA, Frank KAYSER, William D. SHRADER
  • Publication number: 20040022794
    Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Alzheimer's disease, for monitoring the effectiveness of Alzheimer's disease treatment, and for drug development. Alzheimer's Disease-Associated Features (AFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Alzheimer's Disease-Associated Protein Isoforms (APIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated APIs, antibodies immunospecific for APIs, pharmaceutical compositions, diagnostic and therapeutic methods, and kits comprising or based on the same.
    Type: Application
    Filed: October 3, 2002
    Publication date: February 5, 2004
    Inventors: L. Kathryn Durham, David L. Friedman, Herath Mudiyanselage Athula Chandrasiri Herath, Lida H. Kimmel, Rajesh Bhikhu Parekh, David M. Potter, Christian Rohlff, B. Michael Silber, Peter Jeffrey Snyder, Holly Daria Soares, Thomas R. Stiger, P. Trey Sunderland, Robert Reid Townsend, W. Frost White, Stephen A. Williams
  • Publication number: 20030129134
    Abstract: Methods for monitoring and evaluating the efficacy of neuroprotective treatment of a patient suffering from neurological damage by measuring the amount of at least one biomarker in a biological sample taken from the patient during or after treatment.
    Type: Application
    Filed: October 10, 2002
    Publication date: July 10, 2003
    Applicant: Pfizer Inc.
    Inventors: Bertrand L. Chenard, David L. Friedman, Lida Kimmel, Linda F. Nelms, B. Michael Silber, Holly D. Soares, Walter Frost White
  • Publication number: 20020164668
    Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Alzheimer's disease, for monitoring the effectiveness of Alzheimer's disease treatment, and for drug development. Alzheimer's Disease-Associated Features (AFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Alzheimer's Disease-Associated Protein Isoforms (APIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated APIs, antibodies, pharmaceutical compositions, diagnostic and therapeutic methods, and kits comprising or based on the same.
    Type: Application
    Filed: April 3, 2001
    Publication date: November 7, 2002
    Inventors: L. Kathryn Durham, David L. Friedman, Herath Mudiyanselage Athula Chandrasiri Herath, Lida H. Kimmel, Rajesh Bhikhu Parekh, David M. Potter, Christian Rohlff, B. Michael Silber, Thomas R. Stiger, P. Trey Sunderland, Robert Reid Townsend, W. Frost White, Stephen A. Williams